Christine Berni Silverstein Sells 20,070 Shares of Abeona Therapeutics (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO) Director Christine Berni Silverstein sold 20,070 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $5.09, for a total value of $102,156.30. Following the transaction, the director owned 137,722 shares of the company’s stock, valued at approximately $701,004.98. The trade was a 12.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Abeona Therapeutics Stock Performance

Shares of ABEO opened at $4.90 on Friday. The company has a market cap of $265.53 million, a PE ratio of 3.98 and a beta of 1.18. The company has a current ratio of 9.74, a quick ratio of 9.53 and a debt-to-equity ratio of 0.06. The stock has a 50-day moving average price of $5.16 and a 200-day moving average price of $5.57. Abeona Therapeutics Inc. has a 12-month low of $3.93 and a 12-month high of $7.54.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.17. As a group, equities analysts forecast that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Intech Investment Management LLC lifted its stake in shares of Abeona Therapeutics by 19.6% in the 3rd quarter. Intech Investment Management LLC now owns 25,176 shares of the biopharmaceutical company’s stock valued at $133,000 after acquiring an additional 4,127 shares during the last quarter. Creative Planning grew its position in Abeona Therapeutics by 43.0% during the 2nd quarter. Creative Planning now owns 14,310 shares of the biopharmaceutical company’s stock worth $81,000 after acquiring an additional 4,305 shares during the last quarter. Ameritas Investment Partners Inc. purchased a new position in Abeona Therapeutics in the 2nd quarter worth approximately $25,000. Legal & General Group Plc bought a new stake in Abeona Therapeutics in the second quarter valued at approximately $27,000. Finally, Riverwater Partners LLC boosted its stake in shares of Abeona Therapeutics by 45.6% during the third quarter. Riverwater Partners LLC now owns 15,857 shares of the biopharmaceutical company’s stock valued at $84,000 after purchasing an additional 4,963 shares during the period. 80.56% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ABEO has been the subject of a number of research analyst reports. Wall Street Zen downgraded shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Weiss Ratings restated a “sell (d+)” rating on shares of Abeona Therapeutics in a research report on Wednesday, January 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Abeona Therapeutics in a research note on Monday, October 13th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Abeona Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $20.00.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.